Richard L Rauck

Summary

Publications

  1. ncbi Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study
    Richard Rauck
    Carolinas Pain Institute, Winston Salem, North Carolina 27103, USA
    Pain Pract 13:533-8. 2013
  2. doi Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone
    Richard L Rauck
    Carolinas Pain Institute, PA, USA
    Drugs 73:1297-306. 2013
  3. doi Long-term follow-up of a novel implantable programmable infusion pump
    Richard Rauck
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    Neuromodulation 16:163-7. 2013
  4. pmc Peripheral nerve stimulation for the treatment of postamputation pain--a case report
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, NC 27103, USA
    Pain Pract 12:649-55. 2012
  5. doi Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis
    Richard Rauck
    Anesthesiology Pain Management, The Carolinas Pain Institute, Winston Salem, NC 27103, USA
    Pain Pract 13:18-29. 2013
  6. pmc Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia
    Lynn R Webster
    Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, USA
    BMC Neurol 10:92. 2010
  7. doi What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review
    Richard L Rauck
    Medical Director, Carolinas Pain Institute, Center for Clinical Research, Winston Salem, North Carolina 27103, USA
    Pain Pract 9:468-79. 2009
  8. doi Intrathecal ziconotide for neuropathic pain: a review
    Richard L Rauck
    Wake Forest University Health Sciences, Winston Salem, North Carolina 27103, USA
    Pain Pract 9:327-37. 2009
  9. doi Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain
    Richard Rauck
    Carolinas Pain Institute, Wake Forest University, Winston Salem, North Carolina 27103, USA
    Pain Med 9:777-85. 2008
  10. ncbi Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study
    Richard L Rauck
    The Center for Clinical Research, Winston Salem, NC, USA
    Clin J Pain 23:150-8. 2007

Detail Information

Publications24

  1. ncbi Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study
    Richard Rauck
    Carolinas Pain Institute, Winston Salem, North Carolina 27103, USA
    Pain Pract 13:533-8. 2013
    ..Evaluate potential usefulness of a heated lidocaine/tetracaine topical patch for treatment for pain associated with myofascial trigger points (MTPs)...
  2. doi Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone
    Richard L Rauck
    Carolinas Pain Institute, PA, USA
    Drugs 73:1297-306. 2013
    ..e., chronic noncancer pain and pain after orthopedic surgery) are reviewed. Data support that methylnaltrexone is efficacious for the treatment of OIC and has a favorable tolerability profile. ..
  3. doi Long-term follow-up of a novel implantable programmable infusion pump
    Richard Rauck
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    Neuromodulation 16:163-7. 2013
    ..As a follow-up to a previous report on acute six-month data, this study evaluated the efficacy of treatment at one year and the accuracy of drug delivery throughout the study (average of 2.5 years, range 0-3.6 years)...
  4. pmc Peripheral nerve stimulation for the treatment of postamputation pain--a case report
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, NC 27103, USA
    Pain Pract 12:649-55. 2012
    ..The ability to generate significant paresthesia coverage and pain relief with a single lead inserted percutaneously and remotely from the target nerve holds promise for providing relief of postamputation pain...
  5. doi Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis
    Richard Rauck
    Anesthesiology Pain Management, The Carolinas Pain Institute, Winston Salem, NC 27103, USA
    Pain Pract 13:18-29. 2013
    ..The objective of this study was to evaluate the efficacy and safety of OROS hydromorphone extended-release (ER) compared with placebo in patients with moderate to severe pain associated with OA...
  6. pmc Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia
    Lynn R Webster
    Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, USA
    BMC Neurol 10:92. 2010
    ..Current treatment options provide only partial relief and are often limited by poor tolerability. We evaluated the safety and efficacy of a single 60-minute application of NGX-4010, an 8% capsaicin patch, in patients with PHN...
  7. doi What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review
    Richard L Rauck
    Medical Director, Carolinas Pain Institute, Center for Clinical Research, Winston Salem, North Carolina 27103, USA
    Pain Pract 9:468-79. 2009
    ..Opioids have long been an important option in the management of moderate to severe chronic pain, but optimal use requires understanding the variety of choices currently available...
  8. doi Intrathecal ziconotide for neuropathic pain: a review
    Richard L Rauck
    Wake Forest University Health Sciences, Winston Salem, North Carolina 27103, USA
    Pain Pract 9:327-37. 2009
    ..Additional studies are needed to establish the long-term efficacy and safety of ziconotide for neuropathic pain...
  9. doi Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain
    Richard Rauck
    Carolinas Pain Institute, Wake Forest University, Winston Salem, North Carolina 27103, USA
    Pain Med 9:777-85. 2008
    ..Assess the effectiveness and tolerability of a program of gradual dose titration with oxymorphone extended release (ER) for treatment of moderate to severe chronic pain in opioid-naive patients...
  10. ncbi Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study
    Richard L Rauck
    The Center for Clinical Research, Winston Salem, NC, USA
    Clin J Pain 23:150-8. 2007
    ..Peripheral diabetic neuropathy affects between 20% and 45% of patients with diabetes...
  11. ncbi A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain
    Richard L Rauck
    Wake Forest University School of Medicine, The Center for Clinical Research, Carolinas Pain Institute, Winston Salem, North Carolina 27103, USA
    J Pain Symptom Manage 31:393-406. 2006
    ..Slow titration of ziconotide, a nonopioid analgesic, to a low maximum dose resulted in significant improvement in pain and was better tolerated than in two previous controlled trials that used a faster titration to a higher mean dose...
  12. ncbi A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, North Carolina, USA
    J Opioid Manag 2:325-8, 331-3. 2006
    ..The first part of the study, the evaluation phase, was followed by an optional four-month extension phase aimed at evaluating the long-term stability of pain control, SRO dose, and quality of sleep...
  13. ncbi A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low bac
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, North Carolina, USA
    J Opioid Manag 3:35-43. 2007
    ..5 percent versus 19.4 percent, respectively; p = 0.0149). In conclusion, compared to twice-daily OxyContin, once-daily A VINZA resulted in significantly better and earlier improvement ofp hysicalf unction and ability to work...
  14. doi Treatment of post-amputation pain with peripheral nerve stimulation
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, NC, USA The Center for Clinical Research, Winston Salem, NC, USA
    Neuromodulation 17:188-97. 2014
    ..Peripheral nerve stimulation (PNS) could reduce the pain, but it is rarely used because present methods require invasive surgical access and precise placement of the leads in close proximity (≤ 2 mm) with the nerve...
  15. ncbi Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain
    Richard L Rauck
    Piedmont Anesthesia and Pain Consultants, PA, Winston Salem, NC, USA
    J Pain 4:441-7. 2003
    ..This study demonstrated that patients with refractory cancer pain or intolerable side effects achieved better analgesia when managed with patient-activated intrathecal delivery of morphine sulfate via an implanted delivery system...
  16. doi Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain
    Richard L Rauck
    Wake Forest University Health Sciences, Carolinas Pain Institute Center for Clinical Research, Winston Salem, NC, USA
    Curr Med Res Opin 25:2877-85. 2009
    ..This trial evaluated the efficacy and long-term tolerability of a sublingual formulation of the fast-acting opioid fentanyl, for the treatment of BTcP in opioid-tolerant patients with cancer...
  17. ncbi Cystatin C in cerebrospinal fluid is not a diagnostic test for pain in humans
    James C Eisenach
    Department of Anesthesiology and Center for the Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1009, USA
    Pain 107:207-12. 2004
    ..These data suggest that cystatin C concentration in cerebrospinal fluid is an unreliable diagnostic marker for pain in humans...
  18. doi Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies
    Richard L Rauck
    Center for Clinical Research, Winston Salem, North Carolina, USA
    J Pain Symptom Manage 46:219-28. 2013
    ..Treatment options for postherpetic neuralgia (PHN), a complication of herpes zoster, are commonly unsatisfactory and associated with adverse events...
  19. doi Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies
    Srinivas R Nalamachu
    International Clinical Research Institute, Overland Park, Kansas 66211, USA
    Pain Pract 12:449-56. 2012
    ....
  20. ncbi The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to
    Richard L Rauck
    Carolinas Pain Institute, Winston Salem, North Carolina, USA
    J Opioid Manag 2:155-66. 2006
    ..In patients who completed opioid dose titration, A-MQD was significantly better than O-ER for reducing pain and improving sleep, while requiring a lower daily opioid dose...
  21. ncbi Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain
    James C Eisenach
    Department of Anesthesiology and Center for the Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1009, USA
    Pain 105:65-70. 2003
    ..Given the modest effect and common side effects, the role for intrathecal adenosine as a sole agent for the treatment of neuropathic pain may be limited...
  22. ncbi Single-Entity Hydrocodone Extended-Release Capsules in Opioid-Tolerant Subjects with Moderate-to-Severe Chronic Low Back Pain: A Randomized Double-Blind, Placebo-Controlled Study
    Richard L Rauck
    Carolinas Pain Institute, Center for Clinical Research, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Pain Med 15:975-85. 2014
    ..This study was designed to examine the safety and efficacy of HC extended release in opioid-experienced adults with moderate-to-severe chronic low back pain (CLBP)...
  23. ncbi Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel
    Samuel J Hassenbusch
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Pain Symptom Manage 27:540-63. 2004
    ..Based on the best available evidence and expert opinion, consensus recommendations were developed in all these areas. The panel's conclusions may provide a foundation for clinical practice and a rational basis for new research...
  24. ncbi Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival
    Thomas J Smith
    Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Oncol 20:4040-9. 2002
    ..Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory cancer pain, but there are no randomized clinical trial (RCT) data comparing them with comprehensive medical management (CMM)...